THE CONTENT OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND TUMOR RECURRENCE IN SUPERFICIAL BLADDER-CANCER

被引：36

作者：

HASUI, Y ^{[1
]}

MARUTSUKA, K ^{[1
]}

NISHI, S ^{[1
]}

KITADA, S ^{[1
]}

OSADA, Y ^{[1
]}

SUMIYOSHI, A ^{[1
]}

机构：

[1] MIYAZAKI MED COLL,DEPT PATHOL 1,MIYAZAKI 88916,JAPAN

来源：

JOURNAL OF UROLOGY | 1994年 / 151卷 / 01期

关键词：

CARCINOMA; TRANSITIONAL CELL; BLADDER NEOPLASMS; UROKINASE; PLASMINOGEN ACTIVATORS;

D O I：

10.1016/S0022-5347(17)34861-9

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The contents of urokinase-type plasminogen activator were estimated in superficial bladder cancer from 42 patients undergoing transurethral resection for the first time. Tumor recurred in 11 of 16 patients (68.8%) with high urokinase-type plasminogen activator content (8 ng. urokinase-type plasminogen activator per mg. protein and more) and in 12 of 26 (46.2%) with low urokinase-type plasminogen activator content. In the high content group 8 patients (50%) had disease progression compared to 2 (7.7%) in the low content group (p < 0.01). The progression rates in the high urokinase-type plasminogen activator group with stage pTa disease or tumors more than 1 cm. large were significantly higher than those in the low urokinase-type plasminogen activator group (p < 0.05). The recurrence and progression rates in the high content group with stage pT1, grades 2 and 3, single and multiple tumors, and tumors less than 1 cm. large were higher than those in the low content group. The progression-free survival rate in the high content group was significantly lower than that in the low content group (p < 0.005). In conclusion, urokinase-type plasminogen activator content may be a useful marker to predict recurrence and progression of superficial bladder cancer.

引用

页码：16 / 19

页数：4

共 20 条

[1]

BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[2]

CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35

[3] PROGNOSTIC FACTORS IN SUPERFICIAL BLADDER-TUMORS - A STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER - GENITOURINARY TRACT CANCER COOPERATIVE GROUP [J].

DALESIO, O ;

SCHULMAN, CC ;

SYLVESTER, R ;

DEPAUW, M ;

ROBINSON, M ;

DENIS, L ;

SMITH, P ;

VIGGIANO, G ;

SOLOWAY, MS .

JOURNAL OF UROLOGY, 1983, 129 (04) :730-733

[4] PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].

DANO, K ;

ANDREASEN, PA ;

GRONDAHLHANSEN, J ;

KRISTENSEN, P ;

NIELSEN, LS ;

SKRIVER, L .

ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266

[5] TUMOR ENZYMES AND PROGNOSIS IN TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - PREDICTION OF RISK OF PROGRESSION IN PATIENTS WITH SUPERFICIAL DISEASE [J].

DESHPANDE, N ;

MITCHELL, IP ;

HAYWARD, SW ;

LOVE, S ;

TOWLER, JM .

JOURNAL OF UROLOGY, 1991, 146 (05) :1247-1251

[6] THE CONTENT OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AS A PROGNOSTIC FACTOR IN URINARY-BLADDER CANCER [J].

HASUI, Y ;

MARUTSUKA, K ;

SUZUMIYA, J ;

KITADA, S ;

OSADA, Y ;

SUMIYOSHI, A .

INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) :871-873

[7]

HASUI Y, 1989, CANCER RES, V49, P1067

[8] TA AND T1 BLADDER-CANCER - LOCATION, RECURRENCE AND PROGRESSION [J].

HENEY, NM ;

NOCKS, BN ;

DALY, JJ ;

PROUT, GR ;

NEWALL, JB ;

GRIFFIN, PP ;

PERRONE, TL ;

SZYFELBEIN, WA .

BRITISH JOURNAL OF UROLOGY, 1982, 54 (02) :152-157

[9] SUPERFICIAL BLADDER-CANCER - PROGRESSION AND RECURRENCE [J].

HENEY, NM ;

AHMED, S ;

FLANAGAN, MJ ;

FRABLE, W ;

CORDER, MP ;

HAFERMANN, MD ;

HAWKINS, IR .

JOURNAL OF UROLOGY, 1983, 130 (06) :1083-1086

[10]

HISAZUMI H, 1977, UROL RES, V5, P133

← 1 2 →